Edition:
United States

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,477JPY
22 Sep 2017
Change (% chg)

¥-27 (-1.80%)
Prev Close
¥1,504
Open
¥1,509
Day's High
¥1,509
Day's Low
¥1,474
Volume
1,661,000
Avg. Vol
1,366,138
52-wk High
¥2,134
52-wk Low
¥1,397

Latest Key Developments (Source: Significant Developments)

Sumitomo Dainippon Pharma to offer early-retirement program
Tuesday, 30 Aug 2016 03:25am EDT 

Sumitomo Dainippon Pharma Co Ltd <4506.T>: Says it to offer an early-retirement program to employees, who are above 45 years old as of Nov. 30 and worked more than five years (except part of employees) . Says offering period from Sep. 26 to Oct. 14 . Says the employees who take up the offer will retire on Nov. 30 .Says a premium will be added to the normal retirement payment, and the company will provide re-employment support to the retiring employees.  Full Article

Boston Biomedical announces first orphan drug designation for Napabucasin in gastric/gej cancer
Thursday, 23 Jun 2016 12:13pm EDT 

Boston Biomedical : Boston Biomedical announces first orphan drug designation for Napabucasin in gastric/gej cancer .Boston Biomedical - Napabucasin currently investigated in a phase iii clinical trial in combination with paclitaxel in patients with advanced gastric and gej cancer.  Full Article

Sumitomo Dainippon Pharma unit says positive results from two phase 3 clinical studies
Wednesday, 27 Apr 2016 07:40pm EDT 

Sumitomo Dainippon Pharma Co., Ltd:Subsidiary Sunovion Pharmaceuticals Inc announced positive results from the Phase 3 clinical trial program for SUN-101 (glycopyrrolate).SUN-101 that a nebulized long-acting muscarinic antagonist (LAMA), delivered via PARI’s innovative investigational eFlow® nebulizer system (SUN-101/eFlow® ), for people with moderate-to-very severe chronic obstructive pulmonary disease (COPD.The two clinical trials met their primary endpoints with a statistically significant change from baseline in trough forced expiratory volume in one second (FEV1) at Week 12 for both the 50 mcg and 25 mcg dose groups versus placebo.SUN-101/eFlow® also was found to be well-tolerated as a twice-daily maintenance treatment of bronchoconstriction in patients with COPD.  Full Article

Sumitomo Dainippon Pharma raises consolidated full-year outlook for FY 2016
Wednesday, 27 Jan 2016 01:00am EST 

Sumitomo Dainippon Pharma Co., Ltd:Says the consolidated full-year outlook for revenue is 403 billion yen (2 billion yen increased) for FY ending March 2016.Operating profit forecast is 33 billion yen (4 billion yen increased).Ordinary profit forecast is 32.5 billion yen (4 billion yen increased).Net profit forecast is 23 billion yen (3 billion yen increased).  Full Article

Sumitomo Dainippon Pharma raises consolidated mid-year outlook for FY 2016
Friday, 23 Oct 2015 12:00am EDT 

Sumitomo Dainippon Pharma Co., Ltd:Says the company raised the consolidated mid-year outlook for the FY ending March 2016.Revenue forecast increased to 198,900 million yen from 197,500 million yen.Operating profit forecast increased to 16,800 million yen from 11,000 million yen.Ordinary profit forecast increased to 17,500 million yen from 11,000 million yen.Net profit forecast increased to 13,200 million yen from 8,000 million yen.Earnings per share forecast increased to 33.22 yen from 20.14 yen.Comments the decreased expense is the main reason for the forecast.  Full Article

BRIEF-Sumitomo Dainippon Pharma U.S.-based unit enters agreement to divest asthma and allergy products to Covis pharma

* Says its U.S.-based unit Sunovion Pharmaceuticals Inc. has entered into a definitive agreement to divest the U.S. market rights of Sunovion’s three ciclesonide products to Covis Pharma B.V. on July 13(US Eastern Time)